LivaNova Q4 2022 Earnings Report
Key Takeaways
LivaNova PLC reported a 1.8% increase in fourth-quarter revenue, reaching $274.9 million, and a U.S. GAAP diluted earnings per share of $0.03. The company experienced growth across all regions, particularly in the Cardiopulmonary and Neuromodulation business units. Adjusted diluted earnings per share were $0.81.
Fourth-quarter revenue increased 1.8% on a reported basis and 6.2% on a constant-currency basis.
U.S. GAAP diluted earnings per share was $0.03 and adjusted diluted earnings per share was $0.81.
Completed first clinical cases using EssenzTM at two major centers in Europe.
Received ECMO indication 510(k) clearance for LifeSPARCTM.
LivaNova
LivaNova
LivaNova Revenue by Segment
Forward Guidance
LivaNova expects revenue for full-year 2023 to grow between 3 and 5 percent on a constant-currency basis. Adjusted diluted earnings per share for 2023 are expected to be in the range of $2.45 to $2.65, assuming a share count of 54 million for full-year 2023. In 2023, the Company estimates that adjusted free cash flow will be in the range of $80 to $100 million.
Positive Outlook
- Revenue for full-year 2023 to grow between 3 and 5 percent on a constant-currency basis.
- Foreign currency is expected to be a 1 percent tailwind.
- Adjusted diluted earnings per share for 2023 are expected to be in the range of $2.45 to $2.65.
- Share count of 54 million for full-year 2023.
- Adjusted free cash flow will be in the range of $80 to $100 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income